

Literaturübersicht

Citra-Lock™ 4 % Katheterlocklösung

1. Bayes B et al (1999): Sodium Citrate for filling hemodialysis catheters. Nephrol Dial Transplant 14, 2532-2533.
2. Buturovic J et al (1998): Filling hemodialysis catheters in the interdialytic period. Artif Organs 22, 945-947.
3. Grudzinski L et al (2007): Sodium citrate 4% locking solution for central venous dialysis catheters-an effective, more cost-efficient alternative to heparin. Nephrol Dial Transplant 22: 471-476.
4. Hendrickx L et al (2001): A comparative study on the use of low concentrate citrate lock. Int J Artif Organs 24, 208-211.
5. Lok CE et al (2005): Trisodium citrate 4%-an alternative to heparin capping of haemodialysis catheters. Nephrol Dial Transplant 22, 477-483.
6. Meeus G et al (2005): A prospective, randomized, double-blind crossover study on the use of 5% citrate-lock vs 10% citrate-lock. Blood Purif 23, 101-105.
7. Michaud D et al (2001): Four percent trisodium citrate as an effective anticoagulant. Am J Crit Care 10, 351-354.
8. Moran JE and Ash SE (2008): Locking Solutions for Hemodialysis Catheters; Heparin and Citrate. A Position Paper by ASDIN. Seminars in Dialysis 21,1-3.
9. Dreyer G et al (2008): Heparin leak from a hemodialysis catheter causing major bleeding, ultimately leading to transplant rejection and death. HDI Volume 12, Number 4, October 2008, pp. 431-433(3).
10. MacRae JM (2008): Citrate 4% versus Heparin and the Reduction of Thrombosis Studx (CHARTS). Clin J AM Soc Nephrol 3: 369-374.
11. Shanks RMQ (2006): Catheter lock solutions influence staphylococcal biofilm formation on abiotic surfaces. Nephrol Dial Transplant 21: 2247-55.
12. Yon, Calantha K, Low, Chai L (2013): Sodium citrate 4% versus heparin as a lock solution in hemodialysis patients with central venous catheters. Am J Health-Syst-Pharm. Vol 70: 131-136.

13. Vanholder, Raymond et al. (2010): Diagnosis, prevention and treatment of haemodialysis catheter-related bloodstream infections (CRBSI): a position statement of European Renal Best Practice (ERBP). NDT Plus 3: 234-246.

Citra-Lock™ 30 % & Citra-Lock™ 46,7 % Katheterlocklösung

1. Ash SR (2000): Concentrated Sodium Citrate (23%) for Catheter Lock. Haemodialysis International 4:22-31.
2. Weijmer JC (2005): Randomized, Clinical Trial Comparison of Trisodium Citrate 30% and Heparin as Catheter-Locking Solution in Haemodialysis Patients. J Am Soc Nephrol. Sep;16(9):2769-77.
3. Weijmer JC (2002): Superior Antimicrobial Activity of Trisodium Citrate over Heparin for Catheter Locking. Nephrol Dial Transplant 17: 2189-2195.
4. Shanks RM (2006): Catheter Lock Solutions Influence Staphylococcal Biofilm Formation on Abiotic Surfaces. Nephrol Dial Transplant 21, 2247-2255.
5. Nolan JP (2007): Reducing Catheter Related Bacteraemia in Haemodialysis. Vascular Access Soc. 5th Int. Congress of Vascular Access Soc, Nice.
6. Winnett Georgia et al; Trisodium citrate (TSC) 46,7% selectively and safely reduces staphylococcal catheter-related bacteraemia (CRB); Nephrol Dial Transplant (2008) 1 of 7; doi:10.1093/ntd/gfn299
7. VU Amsterdam (2005): Agar diffusion susceptibility test for heparine, Cita-Lock30% en Citra-Lock 46,7%, Microbiological lab VU Amsterdam.
8. Bleyer Anthony B. Use of Antimicrobial Catheter Lock Solutions to Prevent Catheter-Relatet Bacteremia; Clin J Am Soc Nephrol 2; 1073-1078; 2007
9. Bevilacqua J.L. et al; Comparison of trisodium citrate and heparin as catheter-locking solution in hemodialysis patients; J. Bras Nephrol 2001;33 (1); 68-73
10. Organs (1998): Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study, 1998 Nov;22(11):945-7.
11. Hendriks L (2001): A comparative prospective study on the use of low concentrate citrate lock versus heparine lock in permanent dialysis catheters. Int J Artif Organs 2001 Apr; 24(4):208-11.
12. Donlan RM (2001): Biofilms and Device-Associated Infections. Emerging Infectious Diseases, Vol. 7, No. 2, March-April 2001.

13. Karaaslan H (2001): Risk of heparin lock-related bleeding when using indwelling venous catheter in haemodialysis. *Nephrol Dial Transplant* (2001) 16: 2072-2074.
14. Nielsen J (1998): Staphylococcus aureus bacteraemia among patients undergoing dialysis-focus on dialysis catheter-related cases. *Nephrol Dial Transplant* (1998) 13: 139-145.
15. Jean G (2002): Risk factor analysis for long-term tunneled dialysis catheterrelated bacteremias. *Nephron* 2002 Jul;91(3):399-405.
16. Jeffrey S. Berns JS (2002): Preventing Bacterial Infections and Antimicrobial Resistance in Dialysis Patients. *American Journal of Kidney Diseases*, Vol 40, No 5 (November), 2002:pp 886-898.
17. Peleman RA (2000): Changing patterns of antibiotic resistance- update on antibiotic management of the infected vascular access. *Nephrol Dial Transplant* (2000) 15: 1281-1284.
18. Doorenbos CJ (2005): Estimation of trisodium citrate (Citra-Lock™) remaining in central venous catheters after the interdialytic interval. *Nephrol Dial Transplant* (2005) 1 of 3, doi:10.1093/ndt/gfi331.
19. Agharazii M (2005): Estimation of heparin leak into the systemic circulation after central venous catheter heparin lock. *Nephrol Dial Transplant* (2005) 20: 1238-1240, doi:10.1093/ndt/gfh841.
20. Srivastava R (2004): The case of the floating gel. *J Clin Pathol* 2004; 57:1333-1334. doi: 10.1136/jcp.2004.020495.
21. Bosma W. Jacob et al. (2009): Reduction of biofilm formation with trisodium citrate in haemodialysis catheters: a randomized controlled trial; *NDT Advance Access*; Nov. 30, 2009.
22. Van der Meersch, MD (2014): Hemodialysis Catheter Design and Catheter Performance: A Randomized Controlled Trial. *Am J Kidney Dis*. Vol. 64 (6): 902-908.
23. University Hospitals Coventry and Warwickshire, Sanchez, Rufina and Sue Dean (2011): Our experience using Citra-Lock® 30% to maintain the patency of permanent tunneled vascular catheter. *NHS Trust* 2011.
24. Van Hulle F. et al; Citrate-based Locking Solutions are more efficient than Taurolodine-based Locking Solutions to prevent Thrombotic Dysfunction of Tunneled Hemodialysis Catheters: a Retrospective Cohort Study; Poster presentation on the 53rd Congress of ERA-EDTA; Vienna 2016

Citra-HF-Pre™

1. Aman J et al. (2010): Metabolic effects of citrate- vs bicarbonate-based substitution fluid in continuous venovenous hemofiltration: A prospective sequential cohort study. J Crit Care Mar 25(1): 120-7.
2. Oudemans-van Straaten Heleen M et al. (2011): Clinical review: Anticoagulation for continuous renal replacement therapy - heparin or citrate? J Crit Care 15: 202.
3. Monchi M et al. (2004): Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 30: 260-5.
4. Oudemans-van Straaten Heleen M et al. (2009): Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 37(2): 545-552.
5. Nurmohamed S A et al. (2007): Continuous Venocentous Hemofiltration with or without Predilution Regional Citrate Anticoagulation: A Prospective Study. Blood Purif 25: 316-323.
6. Oudemans-van Straaten Heleen M (2007): Review and guidelines for Regional Anticoagulation with Citrate in continuous Hemofiltration. Web 22.04.2015 < http://www.researchgate.net/publication/228784590_Review_and_guidelines_for_regional_anticoagulation_with_citrate_in_continuous_hemofiltration >.